著者

片岡 圭亮 小川 誠司

出版者

日本サイトメトリー学会

雑誌

サイトメトリーリサーチ (ISSN:09166920)

巻号頁・発行日

vol.26, no.2, pp.15-20, 2016

---

<p>PD-1/PD-L1 immune checkpoint pathway, which maintains self-tolerance and limits collateral tissue damage in a physiological state, can be co-opted by cancer cells to evade immune surveillance. Immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 antibodies, can unleash anti-tumor immunity and mediate durable cancer regression. However, the complex biology of this pathway has not been fully elucidated, including the genetic basis of PD-L1 upregulation in cancer. Recently, we have identified a novel genetic mechanism of immune evasion associated with structural variations (SVs) disrupting the 3'-untranlated region (UTR) of the <i>PD-L1</i> gene in a variety of cancers. Despite a large diversity in SV type, these SVs are invariably associated with a marked increase of PD-L1 expression, which promotes tumor progression and immune escape. Here we present an overview of PD-1/PD-L1 immune checkpoint blockade therapy, and highlight the genetic mechanisms of PD-L1 activation, including copy number amplification, promoter replacement, as well as 3'-UTR disruption, with a special focus on their relevance as a biomarker.</p>